0001014108-23-000136.txt : 20230908
0001014108-23-000136.hdr.sgml : 20230908
20230908163335
ACCESSION NUMBER: 0001014108-23-000136
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230616
FILED AS OF DATE: 20230908
DATE AS OF CHANGE: 20230908
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ugwumba Chidozie
CENTRAL INDEX KEY: 0001835544
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39834
FILM NUMBER: 231245715
MAIL ADDRESS:
STREET 1: 158 FILMORE STREET
CITY: DENVER
STATE: CO
ZIP: 80206
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Clene Inc.
CENTRAL INDEX KEY: 0001822791
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 852828339
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6550 SOUTH MILLROCK DRIVE, SUITE G50
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84121
BUSINESS PHONE: 801-676-9695
MAIL ADDRESS:
STREET 1: 6550 SOUTH MILLROCK DRIVE, SUITE G50
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84121
FORMER COMPANY:
FORMER CONFORMED NAME: Chelsea Worldwide Inc.
DATE OF NAME CHANGE: 20200827
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0508
4
2023-06-16
0
0001822791
Clene Inc.
CLNN
0001835544
Ugwumba Chidozie
C/O SYMBIOSIS CAPITAL MANAGEMENT, LLC
609 SW 8TH STREET, SUITE 510
BENTONVILLE
AR
72712
0
0
1
1
Resigned as director 2/15/2023
0
Common Stock
2023-06-16
4
P
0
7500000
0.8
A
13018908
I
By Symbiosis II, LLC
Warrants (Right to buy)
1.5
2023-06-16
4
A
0
7500000
A
2023-06-16
Common Stock
7500000
7500000
I
By Symbiosis II, LLC
Warrants (Right to buy)
1.1
2023-06-16
4
A
0
7500000
A
2023-06-16
Common Stock
7500000
7500000
I
By Symbiosis II, LLC
The price for each Unit is $0.80; one Unit consists of one share of Common Stock of Clene, one Tranche A Warrant and one Tranche B Warrant.
The reporting person purchased a unit consisting of one share of Common Stock of Clene Inc., one Tranche A Warrant, and one Tranche B Warrant. The Tranche B Warrant is for 7,500,000 shares of Common Stock of Clene Inc. at an exercise price of $1.50 per share. The Tranche B Warrant will expire on the earlier of (a) June 16, 2030, or (b) 60 days after the Food and Drug Administration accepts a New Drug Application from Clene Inc.
The reporting person purchased a unit consisting of one share of Common Stock of Clene Inc., one Tranche A Warrant, and one Tranche B Warrant. The Tranche A Warrant is for 7,500,000 shares of Common Stock of Clene Inc. at an exercise price of $1.10 per share. The Tranche A Warrant will expire on the earlier of (a) June 16, 2026, or (b) 60 days after the Food and Drug Administration accepts a New Drug Application from Clene Inc.
/s/Chidozie Ugwumba
2023-09-08